In fact, a recent study3 comprised of 124 patients with COVID‐19 (49% with obesity; 37% with type 2 diabetes) has confirmed the activation of NLRP3 inflammasome upon acquisition of infection with SARS‐CoV‐2 and that NLRP3 inflammasome was active in this patient population. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.